{
    "clinical_study": {
        "@rank": "164947", 
        "arm_group": [
            {
                "arm_group_label": "ASC-01 placebo", 
                "arm_group_type": "Experimental", 
                "description": "A single oral dose of ASC-01 Placebo (sertraline 100 mg)"
            }, 
            {
                "arm_group_label": "Sertraline tablet", 
                "arm_group_type": "Active Comparator", 
                "description": "A single oral dose of sertraline tablets (sertraline 100 mg)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the bioequivalence of ASC-01 Placebo and\n      sertraline Tablet in Japanese healthy male subjects."
        }, 
        "brief_title": "A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers aged 20 to 40 years.\n\n          -  Have a body mass index (BMI) between 18.5 and 25.0 kg/m2 and a weight of at least 50\n             kg.\n\n        Exclusion Criteria:\n\n          -  History of any clinically important disease or disorder which, in the opinion of the\n             Investigator, may either put the volunteer at risk because of participation in the\n             study.\n\n          -  History or presence of gastrointestinal, hepatic, or renal disease or any other\n             condition known to interfere with absorption, distribution, metabolism, or excretion\n             of drugs.\n\n          -  Any clinically significant abnormalities in the physical examination, clinical\n             laboratory values, 12-lead ECG, or vital signs, as judged by the Investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088697", 
            "org_study_id": "031-13-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASC-01 placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sertraline tablet", 
                "intervention_name": "ASC-01", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sertraline"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Osaka", 
                    "country": "Japan"
                }, 
                "name": "Osaka Pharmacology Clinical research Hospital"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Bioequivalence of ASC-01 placebo and sertraline tablet by assessment of Cmax and Area Under Curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "predose, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 144 and 168 hours postdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088697"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUC(0-inf), MRT(0-inf), Tmax, \u03bbz, AUC_%Extrap, T half, CL/F, CL/F/BW, Vz/F and Vz/F/BW of sertraline", 
            "safety_issue": "No", 
            "time_frame": "predose, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 144 and 168 hours postdose"
        }, 
        "source": "Otsuka Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}